Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16018264 | 0.82 | TSHR (0.42) | ALDH1A1GAALMNAMAPTTSHR | |
| Benzene SCHEMBL28061056 | 0.81 | GAA (0.47) | ALDH1A1GAALMNAMAPTTSHR | |
| SCHEMBL223413 | 0.79 | GAA (0.49) | ALDH1A1GAALMNAMAPTTSHR | |
| SCHEMBL2807054 | 0.77 | LMNA (0.54) | ALDH1A1SMN1; SMN2GAALMNAMAPT | |
| SCHEMBL4795046 | 0.77 | GAA (0.41) | ALDH1A1SMN1; SMN2GAALMNAMAPT | |
| Hydrochloric Acid SCHEMBL19119186 | 0.77 | GAA (0.47) | ALDH1A1GAALMNAMAPTTSHR | |
| SCHEMBL6081229 | 0.76 | GAA (0.40) | ALDH1A1MAPK1GAALMNAMAPT | |
| SCHEMBL17562966 | 0.76 | GAA (0.43) | ALDH1A1SMN1; SMN2GAALMNAMAPT | |
| SCHEMBL316185 | 0.73 | ALDH1A1 (0.76) | ALDH1A1SMN1; SMN2GAALMNAMAPT | |
| SCHEMBL6069726 | 0.73 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2GAALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937682-B1 | MET KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-08-12 | — | — | EP | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7547782-B2 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| US-7547782-B2 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| WO-2008157273-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2007041379-A1 | MET KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078140-A1 | MET kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| US-20070078140-A1 | MET kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| CN-1058490-C | Tetrazolinone derivatives | BAYER AGROCHEM KK (JP) | 2000-11-15 | — | — | CN | disclosed |
| EP-0695748-B1 | Tetrazolinone herbicides | BAYER AGROCHEM KK (JP) | 1999-05-06 | — | — | EP | disclosed |
| US-5589439-A | HERBICIDES | NIHON BAYER AGROCHEM K.K. (JP) | 1996-12-31 | — | — | US | disclosed |
| CN-1122333-A | Tetrazolinone derivatives | BAYER AGROCHEM KK (JP) | 1996-05-15 | — | — | CN | disclosed |
| EP-0695748-A1 | Tetrazolinone herbicides | NIHON BAYER AGROCHEM K.K. (JP) | 1996-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078140-A1 | MET kinase inhibitors | MET, ABL1, ERBB2 | ALDH1A1 1225/4885MAPK1 227/4885SMN1; SMN2 4254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.